&lt;p&gt;Clinical Profile of &lt;em&gt;HLA-B27&lt;/em&gt;-Associated Uveitis in an Egyptian Cohort&lt;/p&gt;

Latif, Eiman Abd El; Abdelhalim, Ahmed Shawkat

doi:10.2147/opth.s281860

Cited by 1 publication

(8 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this data is significantly influenced by the study design and the prevalence of the HLA-B27 allele in the general population, reported as 8% in the Caucasian population from western countries and 1–5% in Africa, Asia, and Arabia [ 7 ]. Regarding sex distribution, previous studies conducted in Cuba [ 19 ], Egypt [ 18 ], and Colombia [ 11 ] reported a higher prevalence in males representing 56.5, 68.2 and 79.2% of cases, respectively, that contrasts with our findings since 59% of our patients were female. As for the age of onset, HLA-B27-associated uveitis patients are commonly described as young individuals between their 20' to 40' [ 7 , 20 ].…”

Section: Discussioncontrasting

confidence: 99%

“…On the other hand, the anatomical diagnosis is often described as only anterior. Nonetheless, 17.9% of our patients had vitreous involvement, with 15.4% having a combined anterior and intermediate uveitis presentation; this strongly contrasts with the study done by Abd El Latif et al [ 18 ], who reported vitreous involvement in only 6.5% of their patients, and Monnet et al [ 23 ] who reported vitritis in 10.3% of their patients. In the context of recurrences, our findings are different from those reported by Power et al [ 24 ], with an average number of recurrences of 3.6 (2–22) in contrast to our 1.5 and 1.42 mean of recurrences in six and twelve months.…”

Section: Discussioncontrasting

confidence: 94%

“…HLA-B27-associated uveitis is one of the most frequent specific causes of uveitis according to multiple studies [ 2 , 3 ], representing 7.6% of uveitis in referral centers as was reported by McCannel et al [ 3 ] which in turn closely resembles our findings (7.95%) and those reported by Abd el Latif et al (7.1%) [ 18 ]. However, this data is significantly influenced by the study design and the prevalence of the HLA-B27 allele in the general population, reported as 8% in the Caucasian population from western countries and 1–5% in Africa, Asia, and Arabia [ 7 ].…”

Section: Discussionsupporting

confidence: 91%

“…In addition to demographic traits, our population's clinical spectrum of HLA-B27-associated uveitis slightly varied from the classical presentation described in the literature. Regarding laterality, an unusually high proportion of our patients presented simultaneous bilateral disease (20.58%) when compared to findings previously reported by several authors [ 7 , 11 , 18 – 23 ], including the Classification Criteria for Spondyloarthritis/HLA-B27-associated anterior uveitis by the SUN working group [ 4 ], who reported only 4% of patients with simultaneous bilateral disease. On the other hand, the anatomical diagnosis is often described as only anterior.…”

Section: Discussionsupporting

confidence: 67%

“…Concerning BCVA, our findings showed that our patients had a significantly lesser visual impairment at presentation (0.179 LogMAR) when compared to studies conducted in Egypt [ 18 ] (0.66 LogMAR). We are more closely related to reports from Inanç [ 25 ] in Turkey, whose patients had a mean initial VA of 0.2 LogMAR.…”

Section: Discussioncontrasting

confidence: 44%

See 4 more Smart Citations

Clinical characterization of patients with HLA-B27-associated uveitis and evaluation of the impact of systemic treatment on the recurrence rate: a cross-sectional study

Pineda-Sierra,

Cifuentes-González,

Rojas-Carabali

et al. 2023

J Ophthal Inflamm Infect

View full text Add to dashboard Cite

Introduction Despite HLA-B27-associated uveitis is one of the most frequent etiologies of uveitis worldwide, there are scarce studies on the clinical spectrum of this disease and the implications of therapeutic strategies used in the Latin-American population, with none conducted in Colombia. Thus, this study aimed to describe the clinical characteristics of a cohort of patients with positive HLA-B27-associated uveitis in Colombia and evaluate the impact of systemic treatment on the recurrence rate. Methods We retrospectively reviewed 490 clinical charts of patients with uveitis, searching for those with positive HLA-B27-associated uveitis over eight years in a referral center in Bogotá, Colombia. We used descriptive statistics to summarize demographic and clinical characteristics and conducted a Chi-square test, Fisher Exact test, Spearman correlation, and Mann–Whitney test to assess associations between treatment strategies and the recurrences rate. Results We analyzed 39 patients (59% females) with positive HLA-B27-associated uveitis, with a median age at the first consultation of 44.5 years (Range: 2–80) and a mean follow-up time of 86.4 weeks (1.65 years). Most patients had unilateral uveitis (53.8%) and an anterior anatomical diagnosis (76.6%); two had anterior chamber fibrinous reaction, and only one had hypopyon. Most patients did not show associated systemic symptoms (66.7%). Topical corticosteroids, NSAIDs, methotrexate, mydriatics, and adalimumab were the most used treatments. The most common complications included cataracts, posterior synechiae, and macular edema. We identified that the rate of recurrences decreases over time (r = -0.6361, P = 0.002571), and this decrease seems to be associated with the initiation of disease-modifying antirheumatic drugs (DMARDs) in chronic and recurrent cases. Conclusion The clinical spectrum of HLA-B27-associated uveitis in Colombian patients is distinct from other latitudes. Notably, we found a female predominance, older age at presentation, higher frequency of bilateral and vitreous involvement, and lower frequency of concomitant systemic diseases. Additionally, our results suggest that DMARDs such as methotrexate and biologic agents are good therapeutic options to avoid recurrences in chronic and recurrent cases.

show abstract